Hinge Health, Inc. (OTC:HNGE) reported an insider sale by President James Pursley on March 23, 2026, in which a total of 15,000 shares of Class A Common Stock were sold for approximately $633,927. The companys stock is trading at $40.91, down from the $42.11 close immediately prior to the transactions.
The disposal was executed in three distinct transactions. The first transaction involved 2,256 shares sold at a weighted average price of $41.2126, with execution prices spanning $40.66 to $41.62. The second and largest tranche consisted of 9,838 shares sold at a weighted average price of $42.3571, in a price range of $41.66 to $42.65. The third transaction covered 2,906 shares sold at a weighted average price of $42.7538, with trade prices between $42.66 and $42.86.
After these sales, Pursley directly owns 732,104 shares of Hinge Healths Class A Common Stock. The sales were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that Pursley adopted on June 13, 2025.
Market commentary and analyst coverage referenced alongside the filing emphasize that market participants remain generally constructive on the companys prospects. Analysts are projecting earnings per share of $2.12 for fiscal 2026. An InvestingPro analysis referenced in connection with the transactions describes the stock as appearing undervalued at current levels. The InvestingPro service also offers Pro Research Reports covering HNGE and 1,400+ other U.S. equities for investors seeking deeper research.
Several broker-dealer research updates cited in the notice indicate a range of views and price-target revisions:
- RBC Capital raised its price target on Hinge Health to $55 from $50 and kept an Outperform rating after investor meetings that emphasized HingeSelect, AI, competitive differentiation, and total addressable market expansion.
- Truist Securities reiterated its Buy rating and set a $63 price target following discussions with management about fourth-quarter 2025 results.
- Barclays trimmed its price target to $52 from $60 but retained an Overweight rating, citing improved billings and higher engagements.
- Jefferies initiated coverage with a Hold rating and a $17.50 price target.
In governance news included in the same company update, Tyler Sloat, CFO and COO of Freshworks, was appointed to Hinge Healths board of directors. The statement concluding the companys disclosure characterized these items as part of ongoing evaluations and strategic changes within the company.
This filing provides a snapshot of insider activity and contemporaneous analyst positioning. The sale was structured under an established 10b5-1 plan, and the contemporaneous analyst commentary and price-target movements demonstrate differing valuation perspectives among market participants.
Investors and market observers looking for expanded analysis can access the referenced Pro Research Reports for HNGE and additional U.S. equities through InvestingPro.